Dr. Greg Bleck is Vice President of R&D at Catalent Biologics. He received his BS in Dairy Science and PhD in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression, after which he rejoined a company called Gala Design. During his time with the company, Gala Design grew into Gala Biotech and focused on mammalian cell line development and pharmaceutical manufacturing. Gala Biotech was acquired by Cardinal Heath and was subsequently spun out as part of the formation of Catalent. Since starting the company, the Madison site of Catalent has grown to over 500 employees. In the current role, his focus is the development and acquisition of new products and technologies and was instrumental in Catalent inventing and acquiring the GPEx® suite of technologies, Galacorin®, SMARTag® technology and numerous other products and technologies. These technologies are currently being used to produce 20 commercially approved pharmaceuticals and over 150 different products in various stages of clinical trials. Dr. Bleck has published over 60 research papers and co-authored three book chapters. He is inventor or co-inventor on 20+ issued patents and 15+ patents currently under review. His work at the University of Illinois was highlighted in a book about the greatest advances in the first 150 years of innovation at the University.
- BS, University of Wisconsin–Madison
- PhD, University of Wisconsin–Madison